IL2 and melanoma: To extend this to an in vivo model of adoptive transfer immunotherapy, we next expanded purified TCR-transgenic GP100-reactive CD8+ T cells (47) in IL-2, IL-15, or OMCPmutIL-2 for 2 weeks and adoptively transferred them to C57BL/6 mice bearing established B16 melanoma.